minimizing fatigue and mistakes made by nurses who work night shifts.

Published Date: 26 Apr 2023

Researchers from McGill University found that nurses who receive 40 minutes of bright light exposure prior to their night shifts experience less fatigue and commit fewer mistakes. Following their shifts, the nurses also slept better.

Read Full News

Latest News

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

News All Time

PDGF Pathway in PAH: Setbacks and Promise, With Olivier Sitbon, MD, PhD Olivier Sitbon, MD, PhD

Olivier Sitbon, MD, PhD, reviews PDGF-targeted therapy in PAH, from imatinib's IMPRES trial to new prodrug and antibody approaches.

Dupilumab Scores on Win-Ratio Analysis in Pediatric Asthma: Sharon Dell, MD Sharon Dell, MD

Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

BEAM-302 Base Editing Sustains Protective AAT, With John Hurst, MBBS, PhD John Hurst, MBBS, PhD

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.

Radioactive ion beams successfully treat animal tumors in study

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Does pollution cause cancer?

3.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

4.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

5.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

1.

Fibroma: Understanding the Causes, Symptoms, and Treatment Options

2.

Individualized Hematopoietic Reserve Assessment in Blood Disorders

3.

Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor

4.

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma

5.

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Navigating the Complexities of Ph Negative ALL - Part IV

2.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

3.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

4.

Efficient Management of First line ALK-rearranged NSCLC - Part III

5.

When Unexplained Bruising May Require Blood Testing

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

minimizing fatigue and mistakes made by nurses who work night shifts.

Latest News

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

News All Time

PDGF Pathway in PAH: Setbacks and Promise, With Olivier Sitbon, MD, PhD Olivier Sitbon, MD, PhD

Dupilumab Scores on Win-Ratio Analysis in Pediatric Asthma: Sharon Dell, MD Sharon Dell, MD

BEAM-302 Base Editing Sustains Protective AAT, With John Hurst, MBBS, PhD John Hurst, MBBS, PhD

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Recommended News For You

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

Cancer during young adulthood carries long-term mental toll, study finds

Screening tests that are non-invasive show promise in detecting colorectal cancer.

For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.

Radioactive ion beams successfully treat animal tumors in study

Recommended Articles For You

Exploring New Treatment Strategies for Mantle Cell Lymphoma

Intensive Care Challenges in Advanced Cancer

Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025

Uncovering the Mysteries of Breast Cancer: The Journey to a Cure

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.